Drug-eluting bead TACE combined with apatinib and camrelizumab for treating massive hepatocellular carcinoma
10.13929/j.issn.1672-8475.2024.02.001
- VernacularTitle:载药栓塞微球TACE联合阿帕替尼及卡瑞利珠单抗治疗巨块型肝细胞癌
- Author:
Jinwei CHEN
1
;
Jianzhuang REN
;
Xuhua DUAN
;
Pengfei CHEN
;
Xingshu ZHU
Author Information
1. 郑州大学第一附属医院放射介入科,河南 郑州 450052
- Keywords:
carcinoma,hepatocellular;
chemoembolization,therapeutic;
apatinib;
camrelizumab
- From:
Chinese Journal of Interventional Imaging and Therapy
2024;21(2):65-69
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the value of drug-eluting bead TACE(D-TACE)combined with apatinib and camrelizumab for treating massive hepatocellular carcinoma(HCC).Methods Data of 35 patients with massive HCC who underwent D-TACE sequential apatinib and camrelizumab were retrospectively analyzed.The overall survival(OS)and progression free survival(PFS)were recorded,and the objective response rate(ORR),disease control rate(DCR)and treatment-related adverse event(TRAE)were evaluated.Results Combination treatment were all successfully performed in all 35 cases.At the last follow-up,the median PFS was 8.09 months,and the median OS was 20.00 months.One,3,6,and 12 months after treatments,ORR was 65.71%(23/35),71.43%(25/35),65.71%(23/35)and 60.71%(17/28),respectively,DCR was 94.29%(33/35),88.57%(31/35),80.00%(28/35)and 67.86%(19/28),respectively.TRAE of combination treatment mainly ranged from grade 1 to 2,and all relieved after symptomatic treatments.Conclusion D-TACE combined with apatinib and camrelizumab was effective and safe for treating massive HCC,with controllable adverse reactions.
